[HTML][HTML] Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics

A Witz, J Dardare, M Betz, C Michel… - Biomarker …, 2025‏ - pmc.ncbi.nlm.nih.gov
The use of poly (ADP-ribose) polymerase inhibitors (PARPi) revolutionized the treatment of
BRCA-mutated cancers. Identifying patients exhibiting homologous recombination …

[HTML][HTML] Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics

S Quesada, F Penault-Llorca, X Matias-Guiu… - European Journal of …, 2025‏ - Elsevier
Background Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for
patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent …